Chris Carpenter has been appointed chief medical officer of Cambridge, MA-based Rubius Therapeutics. Carpenter was most recently senior vice president and head of the cancer epigenetics department at GlaxoSmithKline (NYSE: [[ticker:GSK]]). His experience also includes posts at Merck (NYSE: [[ticker:MRK]]) and Harvard Medical School. Earlier this year, Rubius raised $125 million to bring its engineered therapeutic red blood cells into clinical trials.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
